Amgen
Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Amgen Sees Strong Growth for Precision Oncology Drugs in Q3
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium
Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
The firm is encouraged by the MAT2A inhibitor's commercial prospects after seeing its efficacy as a monotherapy in some MTAP-null bladder and lung cancer patients.
Apr 4, 2024
Feb 7, 2024